Table 2.
Immunohistologic analysis of HGAL protein expression in lymphoma subtypes
| Lymphoma subtype | Total positive* | Percent positive |
|---|---|---|
| B-cell lymphoma, N = 384 | ||
| Precursor B-lymphoblastic lymphoma | 1/3 | 33 |
| Follicular lymphoma | ||
| Grade 1 | 23/24 | 96 |
| Grade 2 | 21/21 | 100 |
| Grade 3 | 59/62 | 95 |
| Diffuse large B-cell lymphoma | 103/151 | 68 |
| Mediastinal large B-cell lymphoma | 7/8 | 87 |
| Burkitt lymphoma | 40/40 | 100 |
| Extranodal marginal zone lymphoma | 0/22 | 0 |
| Splenic marginal zone lymphoma | 1/8 | 12 |
| Nodal marginal zone lymphoma | 1/18 | 6 |
| Mantle cell lymphoma | 0/7 | 0 |
| Small lymphocytic lymphoma/CLL | 0/8 | 0 |
| Lymphoplasmacytic lymphoma | 0/12 | 0 |
| T-cell lymphoma, N = 24 | ||
| Precursor T-lymphoblastic lymphoma | 0/5 | 0 |
| Peripheral T-cell lymphoma | 0/10 | 0 |
| Anaplastic large cell lymphoma | 0/5 | 0 |
| Nasal-type NK lymphoma | 0/4 | 0 |
| Plasma cell neoplasms, N = 195 | ||
| Multiple myeloma | 2/167 | 1 |
| Plasma cell leukemia | 2/15 | 13 |
| Plasmacytoma | 0/3 | 0 |
| Monoclonal gammopathy | 0/10 | 0 |
| Hodgkin lymphoma, N = 124 | ||
| Lymphocyte predominant | 12/17 | 70 |
| Classical Hodgkin | 78/107 | 73 |
| Nodular sclerosis | 50/77 | 65 |
| Mixed cellularity | 13/22 | 59 |
*
Cases were scored positive if > 30% of lymphoma cells stained for HGAL